Mira Pharmaceuticals Stock Soars 69% After Positive Study Results

Shares of Mira Pharmaceuticals Inc. (NASDAQ:MIRA) surged by 68.94% to $2.23 in after-hours trading on Wednesday following the announcement of promising preclinical results for its proprietary compound, Mira-55. This significant increase reflects investor enthusiasm about the potential of this non-psychotropic marijuana derivative in the treatment of chronic inflammatory pain.

Preclinical Data Announcement

On Wednesday, Mira Pharmaceuticals submitted an 8-K filing with the Securities and Exchange Commission, detailing new findings from its studies on Mira-55. The research demonstrated that when administered orally, Mira-55 effectively reduced inflammation and normalized pain levels, outperforming injected morphine in a preclinical model of chronic inflammatory pain.

The study’s results revealed that oral doses of Mira-55 restored pain sensitivity to normal levels, proving more effective than morphine, particularly in reducing pain induced by formalin. Furthermore, Mira-55 showed a significant ability to reduce inflammation by specifically targeting CB2 receptors, in contrast to morphine, which only partially alleviated swelling through indirect effects on the central nervous system.

Future Plans and Market Potential

These encouraging findings support the Florida-based company’s ambitions to submit an Investigational New Drug (IND) application aimed at addressing chronic inflammatory pain. The company emphasized the potential of the $70 billion non-opioid pain market as a significant opportunity for growth.

In its most recent earnings report, released on August 14, 2023, Mira Pharmaceuticals reported a loss of 9 cents per share, which was an improvement over analysts’ expectations of a 12-cent loss. The company did not report any revenue for the quarter, and its next earnings report is scheduled for November 11, 2023.

Despite these challenges, Mira Pharmaceuticals has seen a 20% increase in its share price over the past year and a modest 0.76% rise in the past month. On the day of the announcement, approximately 3.7 million shares changed hands, significantly exceeding the stock’s average daily volume of 661,120. Over the past year, MIRA shares have fluctuated between $0.73 and $2.56, and the company currently boasts a market capitalization of $25.37 million.

As investor sentiment remains high, the stock is positioned in the 77th percentile for momentum, according to data from Benzinga Pro. This trend indicates that MIRA is experiencing both short- and medium-term consolidation, alongside a long-term upward trajectory.

Mira Pharmaceuticals’ journey reflects the growing interest in non-opioid pain management solutions. The company’s focus on innovative therapies could not only address significant medical needs but also represent a lucrative opportunity in a changing pharmaceutical landscape.